Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4643230
Max Phase: Preclinical
Molecular Formula: C31H38O6
Molecular Weight: 506.64
Molecule Type: Unknown
Associated Items:
ID: ALA4643230
Max Phase: Preclinical
Molecular Formula: C31H38O6
Molecular Weight: 506.64
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@@H]1CC[C@@H]2[C@@H]1[C@H](OC(=O)c1ccc3ccccc3c1)[C@]1(C3CCCCC3)C[C@@H](OC(=O)CO)[C@@]2(C)O1
Standard InChI: InChI=1S/C31H38O6/c1-19-12-15-24-27(19)28(36-29(34)22-14-13-20-8-6-7-9-21(20)16-22)31(23-10-4-3-5-11-23)17-25(30(24,2)37-31)35-26(33)18-32/h6-9,13-14,16,19,23-25,27-28,32H,3-5,10-12,15,17-18H2,1-2H3/t19-,24-,25-,27-,28+,30+,31-/m1/s1
Standard InChI Key: IDLVJHYEYXKECJ-CVLVEMSBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 506.64 | Molecular Weight (Monoisotopic): 506.2668 | AlogP: 5.44 | #Rotatable Bonds: 5 |
Polar Surface Area: 82.06 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.13 | CX Basic pKa: | CX LogP: 5.70 | CX LogD: 5.70 |
Aromatic Rings: 2 | Heavy Atoms: 37 | QED Weighted: 0.54 | Np Likeness Score: 1.80 |
1. Wu Z, Suppo JS, Tumova S, Strope J, Bravo F, Moy M, Weinstein ES, Peer CJ, Figg WD, Chain WJ, Echavarren AM, Beech DJ, Beutler JA.. (2020) Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition., 11 (9): [PMID:32944138] [10.1021/acsmedchemlett.0c00186] |
Source(1):